VRNA — Verona Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- $8.92bn
- $8.76bn
- $42.28m
Annual cashflow statement for Verona Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -65.1 | -55.6 | -68.7 | -54.4 | -173 |
| Depreciation | |||||
| Non-Cash Items | 21.6 | 23.2 | 18.9 | 17.4 | 55.9 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.11 | -1.56 | -10.7 | -13.9 | -5.74 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -45.1 | -33.3 | -59.9 | -50.2 | -122 |
| Capital Expenditures | -0.082 | -0.012 | -0.029 | 0 | -0.58 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 9.79 | 0 | — | — | — |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 9.71 | -0.012 | -0.029 | 0 | -0.58 |
| Financing Cash Flow Items | -12.9 | -6.85 | -15.4 | 52.2 | 175 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 192 | -6.12 | 141 | 92.9 | 251 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 158 | -39.6 | 79.4 | 43.9 | 128 |